← Herantis Pharma Oyj (HRTIS.HE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Herantis Pharma Oyj (HRTIS.HE)
Pharmaceutical Preparations · market cap $40M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Herantis Pharma Oyj (HRTIS.HE) is a Finnish clinical-stage pharmaceutical company with 13 employees and a market cap of approximately $53M. The company operates three Phase 2 assets: Lymfactin® for secondary lymphedema, a Cerebral Dopamine Neurotrophic Factor (CDNF) program for Parkinson's disease, and cis-UCA ophthalmic solution for dry eye syndrome. No near-term catalysts are listed in the calendar and key financial metrics — cash, runway, and dilution — are not publicly disclosed in the provided data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Lymfactin® (1x10E11 vp) | Phase 2 | Secondary Lymphedema |
| Cerebral Dopamine Neurotrophic Factor | Phase 2 | Parkinson Disease |
| cis-UCA ophthalmic solution 1.0% | Phase 2 | Dry Eye Syndrome |
Price & technical context
3-month
-23.5%
6-month
-13.3%
12-month
-26.3%
52-wk range
$1.37–$2.78
vs 50-day MA
-11.1%
vs 200-day MA
-25.6%
Realized vol
60.2%
Max drawdown
-50.7%
Daily closes through 2026-10-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HRTIS.HE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.